Skip to main content

Carl J Pepine, MD

Cardiologist (Heart Specialist)

Photo of Carl J Pepine

Research at a glance

Top areas of exploration

  • Coronary Disease , 198 publications
  • Myocardial Ischemia , 191 publications
  • Coronary Artery Disease , 156 publications
  • Hypertension , 146 publications

Research activity

1,060 publications

53,745 citations

Why is this important?

Focus

My career has focused on improving our understanding of mechanisms underlying ischemic heart disease (IHD) and related adverse outcomes. I have conducted extensive investigations in coronary artery disease (CAD), hypertension, treatment resistant hypertension, vascular biology, and therapeutic applications related to vascular dysfunction. My work has centered on how IHD becomes manifest with and without large coronary artery obstructive disease (CAD). Much of this work is concentrated in women with known or suspect IHD. A major goal of clinical research is development of actionable information of sufficient power to alter medical care and improve patient health by information obtained through performance of clinical trials. To this end, I conceived and led the first randomized controlled international mega-trial of blood pressure control for patients with CAD (INVEST). My experience also includes being a principal investigator (PI) in multiple NHLBI-funded projects [Women’s Ischemia Syndrome Evaluation (WISE), WISE-CVD, WISE HFpEF, MayWEST, Asymptomatic Cardiac Ischemia Pilot (ACIP), Psychophysiologic Interventions of Myocardial Ischemia (PIMI), Bypass Angioplasty Revascularization Investigation 2-Diabetes Trial (BARI2D), etc.] and many other industry-sponsored studies. More recently I have been working in cardiovascular recovery and regeneration with cell based therapies as a PI in the NHLBI Cardiovascular Cell Therapy Network (CCTRN)- 1 and 2, as well as studies funded by the the cell and gene biomedical industry.

Active clinical trials

LIBREXIA-ACS

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
EVOLVE

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic…

Investigator
Carl J Pepine
Status
Accepting Candidates
Ages
18 Years - 99 Years
Sexes
All

My publications

1060 publications

2024

Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial

Circulation: Cardiovascular Interventions

Publisher's site

2024

Arterial stiffness assessment in coronary microvascular dysfunction and heart failure with preserved ejection fraction: An initial report from the WISE-CVD continuation study.

American heart journal plus : cardiology research and practice

PubMed Publisher's site

2024

Comparison of risk profiles of participants in the Women's IschemiA TRial to Reduce events In non-ObstRuctive CAD (WARRIOR) trial, using Coronary Computed Tomography Angiography vs Invasive Coronary Angiography.

Progress in cardiovascular diseases

PubMed Publisher's site

2024

Contributors to high left ventricular ejection fraction in women with ischemia and no obstructive coronary artery disease: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) Study.

American heart journal

PubMed Publisher's site

2024

Elevated high-density lipoprotein cholesterol and adverse outcomes in women with symptoms of ischemic heart disease.

American heart journal plus : cardiology research and practice

PubMed Publisher's site